Journal of Pharmaceutical Sciences and Drug Development

Antiviral Drugs Effective for New Emerging Monkey-pox Virus

Janney Mathew^{* *}Correspondence: Janney Mathew, Editorial Office, Journal of Pharmaceutical Sciences and Drug Development, Morocco, Email:

Author info »

Introduction

A zoonotic orthopoxvirus called human monkeypox has symptoms that resemble smallpox. When people come into contact with diseased animals, they may unintentionally contract monkeypox. According to reports, the virus can also spread through close physical contacts, such as skin-to-skin contact or sexual contact, respiratory droplets, and by household items like towels and blankets. There are numerous medical counter measures on hand for orthopoxviruses like monkeypox. JYNNEOS (live, replicationincompetent vaccinia virus) and ACAM2000® are the two vaccines that are now available (live, replication competent vaccinia virus). Although supportive care is usually sufficient for the majority of monkeypox cases, which have a moderate and self-limited disease, there are antivirals (such as tecovirimat, brincidofovir, and cidofovir) and Vaccinia Immune Globulin Intravenous (VIGIV) that can be used as treatments. Antivirals should be taken into account in cases of severe illness, immunosuppressed individuals, children, pregnant and nursing women, complicated lesions, and when lesions develop close to the mouth, eyes, or genitalia. This quick review's goal is to give a brief description of each of these defenses [1].

Public health experts are concerned that the emergence of a new outbreak brought on by the monkeypox virus could pose a new threat while the world continues to be challenged by the coronavirus disease 2019 (COVID-19) pandemic. The genus orthopoxviruses, which also includes the variola, Cowpox (CPX), and vaccinia viruses, includes the doublestranded DNA virus known as the monkeypox virus. The monkeypox virus was initially discovered in monkeys, but it also naturally infects rope squirrels, tree squirrels, Gambian pouched rats, and dormice [2].

The Variola Virus (VARV), the cause of smallpox, still has research supplies in safe labs despite the eradication of naturally occurring smallpox. There have been worries that VARV could be utilised as a biological weapon because it is feasible for the virus to exist in secret storage or to be revived by synthetic biology. The US government has stored TPOXX®, a smallpox antiviral medicine from SIGA Technologies, as well as smallpox immunizations in anticipation of such an occurrence. Although vaccination is useful as a pre-exposure prophylactic, protection is only somewhat effective when given after exposure. Unless there is a smallpox outbreak, general use of the vaccine is prohibited due to safety concerns. The FDA has authorised the use of TPOXX following a verified diagnosis of smallpox illness [ 3 ].

TPOXX's active pharmaceutical ingredient, tecovirimat, targets a highly conserved orthopoxviral protein and prevents the virus from spreading further. Although the vaccine and TPOXX have different indications for use, they can be used concurrently. This is especially true if the TPOXX indication is extended to include post-exposure prophylaxis. It is crucial to comprehend any potential interactions between the vaccination and TPOXX. The ACAM2000TM live attenuated smallpox vaccination was administered to monkeys in the research shown here, along with tecovirimat or a placebo. The vaccine's protective effectiveness against a deadly Monkeypox Virus (MPXV) challenge and immune responses were assessed [4].

In two investigations, primary and anamnestic humoral immune responses were comparable regardless of the use of tecovirimat, while the third research revealed a decline in humoral immunity induced by the vaccination. All12of12 vaccined/placebo-treatedmice and 12 of 13 vaccined/tecovirimat-treated animals survived the lethal MPXV challenge. When compared to animals receiving a placebo, the clinical symptoms of illness were more pronounced in tecovirimat-treated animals. This implies that concurrent administration of TPOXX and ACAM2000 may alter the immunogenicity of the latter [5].

References

1. Kalil, Haitham., et al. "Membrane Scaffolds Silver Nanoparticles As a New Platform of Antiviral Personal Protective Equipment for COVID-19." IOP Publishing 68(2020): 3572.

   [Google Scholar] [Cross Ref]

2. Bano, R., et al. "The Zoonotic Disease Human Monkey Pox: An Insights into Epidemiological, Clinical, and Preventative Features." Pak. J Med  Health Sci 16.5 (2022): 1289-1289.

   [Google Scholar] [Cross Ref]

3. Galdiero, S., et al. “Silver nanoparticles as potential antiviral agents.” Molecules. 16.10(2011):8894-8918.

   [Google Scholar] [Cross Ref]

4. Angahar, LT., “An Overview of Monkey-pox Disease.” Am J Curr Microbiol  6.1(2018):39-51.

   [Google Scholar] [Cross ref]

5. Tahiliani, V., & Kolotylo, T., “Monkey-Pox Virus and It’s Impact.” J Infect Dis Epidemiol 8.8(2022):273.

   [Google Scholar] [Cross Ref]